Sign in
Taking people in NetherlandsPhase 4

Methotrexate compared with prednisone as first treatment for sarcoidosis in the lungs

Compares methotrexate with prednisone as first treatment in adults with pulmonary sarcoidosis.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
'S-Gravenhage, 's-Hertogenbosch, Amsterdam, Arnhem, Breda, Eindhoven, Enschede, Groningen, Heerlen, Leeuwarden, Leiden, Nieuwegein, Nijmegen, Rotterdam, Venlo, and Zwolle, NetherlandsSee the 18 sites
Registry title
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
Status
Recruiting
Phase
Phase 4
People taking part
132 people, planned
Started
19 Nov 2024
Planned end
1 Mar 2025
Type of study
Interventional
Record updated
19 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sarcoidosis in the lungs who need treatment for the first time. It compares methotrexate with prednisone.

Age
18 years or older
Sex
All sexes can join
Disease stage
Sarcoidosis affecting the lung tissue, seen on X-ray or CT scan in the last three months. The lungs must need treatment.
Earlier treatment
No earlier treatment that weakens the immune system for sarcoidosis. No such treatment for another disease in the past three months.
Biomarker or test result
Lung tests must show FVC ≤90% of predicted, or DLCO ≤70% of predicted, or a drop of ≥5% FVC or ≥10% DLCO in the past year.

Main reasons for not taking part

  • Pregnant, breastfeeding, or planning pregnancy, breastfeeding or fathering a child during the study or within 90 days after the last dose
  • Severe kidney problems (creatinine clearance <30 ml/min) or liver problems (bilirubin >5 mg/dl or 85,5 micromole/l)
  • Bone marrow problems with very low white cells, platelets or red cells
  • Severe infections such as tuberculosis, HIV, parasites or other immune weakness
  • Ulcers in the mouth, stomach or duodenum

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Diagnosis of sarcoidosis according to the ATS/ERS/WASOG criteria (7), in case of absent histology a diagnosis of sarcoidosis can also be established in a multidisciplinary team meeting in a sarcoidosis expert center based on a highly suggestive clinical and radiological picture (18, 19)
  • Age ≥18 years
  • A pulmonary indication for treatment and parenchymal involvement on X-ray or CT-scan conducted within three months before inclusion (determined by the treating physician and conform current guidelines)
  • A forced vital capacity (FVC) of ≤90% of predicted, or a diffusion capacity of the lung for carbon monoxide (DLCO) ≤70% of predicted, or ≥5% FVC decline/≥10% DLCO decline in the past year. For pulmonary functions tests GLI reference values are used

Who cannot take part

  • Previous immunosuppressive treatment for sarcoidosis
  • Any condition or circumstance that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures
  • Use of systemic immunosuppressive therapy within the preceding three months for another disease than sarcoidosis
  • Contra-indication for methotrexate or corticosteroids: • severely impaired renal function (creatinine clearance <30 ml/min) • impaired hepatic function (serum bilirubin-value >5 mg/dl or 85,5 micromole/l) • bone marrow insufficiency with severe leukopenia, thrombocytopenia, or anaemia • severe acute or chronic infections, such as tuberculosis, HIV, parasitic infections or other immunodeficiency syndromes • mouth, stomach or duodenal ulcers
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study treatment or within 90 days after the last dose in the randomized study phase. For males; planning to pro-create during the study or within 90 days after the last dose of the randomized study phase

Where in Netherlands

  • Haaglanden Medisch Centrum Stichting'S-Gravenhage, NetherlandsTaking people
  • Jeroen Bosch Hospital's-Hertogenbosch, NetherlandsTaking people
  • Academisch Medisch CentrumAmsterdam, NetherlandsTaking people
  • OLVGAmsterdam, NetherlandsTaking people
  • Vrije UniversiteitAmsterdam, NetherlandsTaking people
  • Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
  • Amphia HospitalBreda, NetherlandsTaking people
  • Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
  • Medisch Spectrum TwenteEnschede, NetherlandsTaking people
  • Stichting Martini ZiekenhuisGroningen, NetherlandsTaking people
  • Zuyderland Medisch Centrum StichtingHeerlen, NetherlandsTaking people
  • Medisch Centrum Leeuwarden B.V.Leeuwarden, NetherlandsTaking people
  • LUMCLeiden, NetherlandsTaking people
  • Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
  • Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsTaking people
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
  • Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsTaking people
  • Isala Klinieken StichtingZwolle, NetherlandsTaking people

About the trial

What the trial wants to find out

Investigate the effectiveness and tolerability of methotrexate as firstline therapy in patients with pulmonary sarcoidosis compared with prednisone.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis - A randomized controlled trial
Plain-language title
Methotrexate compared with prednisone as first treatment for sarcoidosis in the lungsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
19 November 2024